The DETA Study
Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: The “DETA” randomised controlled trial
In the DETA study, we will investigate whether dapagliflozin (a drug used in type 2 diabetes that also helps people to lose weight) can be used to improve overall physical health, measured by how easy it is to undertake everyday physical activities. We will also investigate whether combining dapagliflozin with an exercise programme can make benefits even greater, as well as how dapagliflozin (with or without exercise) affects blood sugar levels, heart health (measured using MRI) and other markers of overall heath.
We are looking for 135 adults with type 2 diabetes, who will be randomly allocated to receive one of the following treatments for 24 weeks (alongside any existing medications):
Dapagliflozin: A daily tablet of dapagliflozin
Dapagliflozin and exercise: A daily tablet of dapagliflozin alongside a personalised supervised exercise programme, delivered by our physical activity experts.
Diet control: Personalised support from our research dietitians, with the aim of losing the same amount of weight the people taking dapagliflozin (approximately 3 kg).
Participants will be asked to come Leicester Diabetes Centre before they are allocated to a group (“baseline”) and then after 12 and 24 weeks of treatment. They will also be invited to undertake a scan of their heart at the beginning and end of the study to investigate the effect of the treatments on their heart.
We are looking for people to take part in the DETA study. If you are interested in taking part, please contact the study team for more information.